Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 8, 2013, Pages 1249-1259

  Di Domenico, Fabio ^a   Coccia, Raffaella ^a   Cocciolo, Annalisa ^a   Murphy, M Paul ^c   Cenini, Giovanna ^b   Head, Elizabeth ^b,c   Butterfield, D Allan ^b,c   Giorgi, Alessandra ^a   Schinina, Maria Eugenia ^a   Mancuso, Cesare ^d   Cini, Chiara ^a   Perluigi, Marzia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer disease; Autophagy; Down syndrome; Oxidative stress; Proteasome; Trisomy 21

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMYLOID BETA PROTEIN; CATHEPSIN D; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE REGULATED PROTEIN 78; PROTEASOME; UBIQUITIN CARBOXYL TERMINAL HYDROLASE 1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; V0 ADENOSINE TRIPHOSPHATASE;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; ARTICLE; AUTOPHAGOSOME; BRAIN; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OXIDATION; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; PROTEOSTASIS DEFICIENCY;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; CATHEPSIN D; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; FRONTAL LOBE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHAGOSOMES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CARBONYLATION; PROTEOMICS; PROTEOSTASIS DEFICIENCIES; TAU PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84877315419     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.04.013     Document Type: Article

References (88)

1. Ness S., Rafii M., Aisen P., Krams M., Silverman W., Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat. Rev. Drug Discov. 2012, 11:655-656.
2. Busciglio J., Pelsman A., Helguera P., Ashur-Fabian O., Pinhasov A., Brenneman D.E., Gozes I. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr. Pharm. Des. 2007, 13:1091-1098.
3. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., Yankner B.A. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002, 33:677-688.
4. de Haan J.B., Susil B., Pritchard M., Kola I. An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the "gene dosage effect" hypothesis. J. Neural Transm. Suppl. 2003, 67-83.
5. Lott I.T., Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:172-178.
6. Cenini G., Dowling A.L., Beckett T.L., Barone E., Mancuso C., Murphy M.P., Levine H., Lott I.T., Schmitt F.A., Butterfield D.A., Head E. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim. Biophys. Acta 2012, 1822:130-138.
7. Mann D.M., Yates P.O., Marcyniuk B., Ravindra C.R. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol. Appl. Neurobiol. 1986, 12:447-457.
8. Visser F.E., Aldenkamp A.P., van Huffelen A.C., Kuilman M., Overweg J., van Wijk J. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am. J. Ment. Retard. 1997, 101:400-412.
9. Wisniewski K.E., Dalton A.J., McLachlan C., Wen G.Y., Wisniewski H.M. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 1985, 35:957-961.
10. Wegiel J., Wisniewski H.M., Dziewiatkowski J., Popovitch E.R., Tarnawski M. Differential susceptibility to neurofibrillary pathology among patients with Down syndrome. Dementia 1996, 7:135-141.
11. Leverenz J.B., Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol. 1998, 150:296-304.
12. Head E., Lott I.T., Patterson D., Doran E., Haier R.J. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J. Alzheimers Dis. 2007, 11:61-76.
13. Head E., Doran E., Nistor M., Hill M., Schmitt F.A., Haier R.J., Lott I.T. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia In down syndrome. J. Alzheimers Dis. 2011, 23:399-409.
14. Head E., Lott I.T. Down syndrome and beta-amyloid deposition. Curr. Opin. Neurol. 2004, 17:95-100.
15. Schupf N., Sergievsky G.H. Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry 2002, 180:405-410.
16. Perluigi M., Butterfield D.A. Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr. Gerontol. Geriatr. Res. 2012, 2012:724904.
17. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in-vitro. Nature 1995, 378:776-779.
18. Reynolds G.P., Cutts A.J. Free radical damage in Down's syndrome brain. Biochem. Soc. Trans. 1993, 21:221S.
19. Odetti P., Angelini G., Dapino D., Zaccheo D., Garibaldi S., Dagna-Bricarelli F., Piombo G., Perry G., Smith M., Traverso N., Tabaton M. Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Commun. 1998, 243:849-851.
20. Perluigi M., di Domenico F., Fiorini A., Cocciolo A., Giorgi A., Foppoli C., Butterfield D.A., Giorlandino M., Giorlandino C., Schinina M.E., Coccia R. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl. 2011, 5:167-178.
21. Nijholt D.A., De Kimpe L., Elfrink H.L., Hoozemans J.J., Scheper W. Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr. Med. Chem. 2011, 18:2459-2476.
22. Klionsky D.J. An autophagy glossary. Autophagy 2010, 6.
23. Riederer B.M., Leuba G., Vernay A., Riederer I.M. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp. Biol. Med. (Maywood) 2011, 236:268-276.
24. Scheper W., Nijholt D.A., Hoozemans J.J. The unfolded protein response and proteostasis in Alzheimer disease: preferential activation of autophagy by endoplasmic reticulum stress. Autophagy 2011, 7:910-911.
25. Butterfield D.A., Perluigi M., Reed T., Muharib T., Hughes C.P., Robinson R.A., Sultana R. Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid. Redox Signal. 2012, 17:1610-1655.
26. Mangialasche F., Polidori M.C., Monastero R., Ercolani S., Camarda C., Cecchetti R., Mecocci P. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res. Rev. 2009, 8:285-305.
27. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 2000, 75:436-439.
28. Grimm S., Horlacher M., Catalgol B., Hoehn A., Reinheckel T., Grune T. Cathepsins D and L reduce the toxicity of advanced glycation end products. Free Radic. Biol. Med. 2012, 52:1011-1023.
29. Poon H.F., Hensley K., Thongboonkerd V., Merchant M.L., Lynn B.C., Pierce W.M., Klein J.B., Calabrese V., Butterfield D.A. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2005, 39:453-462.
30. Pagano G., Castello G. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv. Exp. Med. Biol. 2012, 724:291-299.
31. Gestwicki J.E., Garza D. Protein quality control in neurodegenerative disease. Prog. Mol. Biol. Transl. Sci. 2012, 107:327-353.
32. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., Mehta P.D., Buxbaum J., Haroutunian V., Nixon R.A. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging 2004, 25:1263-1272.
33. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
34. Umeda T., Tomiyama T., Sakama N., Tanaka S., Lambert M.P., Klein W.L., Mori H. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J. Neurosci. Res. 2011, 89:1031-1042.
35. Chafekar S.M., Zwart R., Veerhuis R., Vanderstichele H., Baas F., Scheper W. Increased Abeta1-42 production sensitizes neuroblastoma cells for ER stress toxicity. Curr. Alzheimer Res. 2008, 5:469-474.
36. Yoshida H. ER stress and diseases. FEBS J. 2007, 274:630-658.
37. Owen J.B., Di Domenico F., Sultana R., Perluigi M., Cini C., Pierce W.M., Butterfield D.A. Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J. Proteome Res. 2009, 8:471-482.
38. Vembar S.S., Brodsky J.L. One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 2008, 9:944-957.
39. Goder V. Roles of ubiquitin in endoplasmic reticulum-associated protein degradation (ERAD). Curr. Protein Pept. Sci. 2012, 13:425-435.
40. Gong B., Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect. 2007, 20:365-370.
41. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004, 279:13256-13264.
42. Butterfield D.A., Gnjec A., Poon H.F., Castegna A., Pierce W.M., Klein J.B., Martins R.N. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 2006, 10:391-397.
43. Sultana R., Boyd-Kimball D., Cai J., Pierce W.M., Klein J.B., Merchant M., Butterfield D.A. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 2007, 11:153-164.
44. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 2002, 33:562-571.
45. Hegde A.N. The ubiquitin-proteasome pathway and synaptic plasticity. Learn. Mem. 2010, 17:314-327.
46. Grune T., Reinheckel T., Joshi M., Davies K.J.A. Proteolysis in cultured liver epithelial-cells during oxidative stress - role of the multicatalytic proteinase complex, proteasome. J. Biol. Chem. 1995, 270:2344-2351.
47. Rivett A.J. The effect of mixed-function oxidation of enzymes on their susceptibility to degradation by a nonlysosomal cysteine proteinase. Arch. Biochem. Biophys. 1985, 243:624-632.
48. Giulivi C., Pacifici R.E., Davies K.J.A. Exposure of hydrophobic moieties promotes the selective degradation of hydrogen peroxide-modified hemoglobin by the multicatalytic proteinase complex, proteasome. Arch. Biochem. Biophys. 1994, 311:329-341.
49. Butterfield D.A., Stadtman E.R. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 1997, 2:161-191.
50. Grune T., Reinheckel T., Davies K.J. Degradation of oxidized proteins in mammalian cells. FASEB J. 1997, 11:526-534.
51. Ding W.X., Ni H.M., Gao W., Yoshimori T., Stolz D.B., Ron D., Yin X.M. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am. J. Pathol. 2007, 171:513-524.
52. Imaizumi K. Autophagy is activated for cell survival after ER stress. J. Pharmacol. Sci. 2007, 103:45P-P.
53. Yorimitsu T., Nair U., Yang Z.F., Klionsky D.J. Endoplasmic reticulum stress triggers autophagy. J. Biol. Chem. 2006, 281:30299-30304.
54. Barnett A., Brewer G.J. Autophagy in aging and Alzheimer's disease: pathologic or protective?. J. Alzheimers Dis. 2011, 25:385-394.
55. Kaushik S., Cuervo A.M. Autophagy as a cell-repair mechanism: activation of chaperone-mediated autophagy during oxidative stress. Mol. Aspects Med. 2006, 27:444-454.
56. Bursch W., Hochegger K., Torok L., Marian B., Ellinger A., Hermann R.S. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J. Cell Sci. 2000, 113(Pt 7):1189-1198.
57. Di Fonzo A., Chien H.F., Socal M., Giraudo S., Tassorelli C., Iliceto G., Fabbrini G., Marconi R., Fincati E., Abbruzzese G., Marini P., Squitieri F., Horstink M.W., Montagna P., Libera A.D., Stocchi F., Goldwurm S., Ferreira J.J., Meco G., Martignoni E., Lopiano L., Jardim L.B., Oostra B.A., Barbosa E.R., Bonifati V. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007, 68:1557-1562. N. Italian Parkinson Genetics.
58. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., Al-Din A., Hillmer A.M., Karsak M., Liss B., Woods C.G., Behrens M.I., Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191.
59. Di Domenico F., Sultana R., Ferree A., Smith K., Barone E., Perluigi M., Coccia R., Pierce W., Cai J., Mancuso C., Squillace R., Wiengele M., Dalle-Donne I., Wolozin B., Butterfield D.A. Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease. Antioxid. Redox Signal. 2012, 17:1490-1506.
60. Zoncu R., Bar-Peled L., Efeyan A., Wang S., Sancak Y., Sabatini D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 2011, 334:678-683.
61. Lee J.H., Yu W.H., Kumar A., Lee S., Mohan P.S., Peterhoff C.M., Wolfe D.M., Martinez-Vicente M., Massey A.C., Sovak G., Uchiyama Y., Westaway D., Cuervo A.M., Nixon R.A. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010, 141:1146-1158.
62. Morawe T., Hiebel C., Kern A., Behl C. Protein homeostasis, aging and Alzheimer's disease. Mol. Neurobiol. 2012, 46:41-54.
63. Grkovic S., O'Reilly V.C., Han S., Hong M., Baxter R.C., Firth S.M. IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene Jul. 2 2012, 10.1038/onc.2012.264.
64. Li J., Ni M., Lee B., Barron E., Hinton D.R., Lee A.S. The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells. Cell Death Differ. 2008, 15:1460-1471.
65. Middeldorp J., Hol E.M. GFAP in health and disease. Prog. Neurobiol. 2011, 93:421-443.
66. Korolainen M.A., Auriola S., Nyman T.A., Alafuzoff I., Pirttila T. Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol. Dis. 2005, 20:858-870.
67. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience 1993, 54:15-36.
68. Gomes F.C., Paulin D., Moura Neto V. Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation. Braz. J. Med. Biol. Res. 1999, 32:619-631.
69. Beach T.G., Walker R., McGeer E.G. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 1989, 2:420-436.
70. Bandyopadhyay U., Sridhar S., Kaushik S., Kiffin R., Cuervo A.M. Identification of regulators of chaperone-mediated autophagy. Mol. Cell 2010, 39:535-547.
71. Kiffin R., Christian C., Knecht E., Cuervo A.M. Activation of chaperone-mediated autophagy during oxidative stress. Mol. Biol. Cell 2004, 15:4829-4840.
72. Boyd-Kimball D., Castegna A., Sultana R., Poon H.F., Petroze R., Lynn B.C., Klein J.B., Butterfield D.A. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res. 2005, 1044:206-215.
73. Grimm S., Ernst L., Grotzinger N., Hohn A., Breusing N., Reinheckel T., Grune T. Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. Free Radic. Res. 2010, 44:1013-1026.
74. Benes P., Vetvicka V., Fusek M. Cathepsin D-many functions of one aspartic protease. Crit. Rev. Oncol. Hematol. 2008, 68:12-28.
75. Schuur M., Ikram M.A., van Swieten J.C., Isaacs A., Vergeer-Drop J.M., Hofman A., Oostra B.A., Breteler M.M., van Duijn C.M. Cathepsin D gene and the risk of Alzheimer's disease: a population-based study and meta-analysis. Neurobiol. Aging 2011, 32:1607-1614.
76. Aluise C.D., Robinson R.A., Beckett T.L., Murphy M.P., Cai J., Pierce W.M., Markesbery W.R., Butterfield D.A. Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol. Dis. 2010, 39:221-228.
77. Cataldo A.M., Barnett J.L., Berman S.A., Li J., Quarless S., Bursztajn S., Lippa C., Nixon R.A. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 1995, 14:671-680.
78. Bernstein H.G., Bruszis S., Schmidt D., Wiederanders B., Dorn A. Immunodetection of cathepsin-D in neuritic plaques found in brains of patients with dementia of Alzheimer type. J. Hirnforsch. 1989, 30:613-618.
79. Cataldo A.M., Thayer C.Y., Bird E.D., Wheelock T.R., Nixon R.A. Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin. Brain Res. 1990, 513:181-192.
80. Hook V., Schechter I., Demuth H.U., Hook G. Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol. Chem. 2008, 389:993-1006.
81. Choy R.W., Cheng Z., Schekman R. Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid beta (Abeta) production in the trans-Golgi network. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2077-E2082.
82. Karch C.M., Prudencio M., Winkler D.D., Hart P.J., Borchelt D.R. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7774-7779.
83. Butler D., Hwang J., Estick C., Nishiyama A., Kumar S.S., Baveghems C., Young-Oxendine H.B., Wisniewski M.L., Charalambides A., Bahr B.A. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One 2011, 6:e20501.
84. Sultana R., Butterfield D.A. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J. Bioenerg. Biomembr. 2009, 41:441-446.
85. Yao J., Rettberg J.R., Klosinski L.P., Cadenas E., Brinton R.D. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol. Aspects Med. 2011, 32:247-257.
86. Soto C., Estrada L.D. Protein misfolding and neurodegeneration. Arch. Neurol. 2008, 65:184-189.
87. McClellan A.J., Tam S., Kaganovich D., Frydman J. Protein quality control: chaperones culling corrupt conformations. Nat. Cell Biol. 2005, 7:736-741.
88. Cataldo A.M., Mathews P.M., Boiteau A.B., Hassinger L.C., Peterhoff C.M., Jiang Y., Mullaney K., Neve R.L., Gruenberg J., Nixon R.A. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol. 2008, 173:370-384.